Intrathecal baclofen therapy for spasticity of cerebral origin: Cerebral palsy and brain injury

Neuromodulation

Volumn 2, Issue 2, 1999, Pages 120-132

  Nuttin, Bart ^a,e   Ivanhoe, Cindy ^b,c   Albright, Leland ^b,c   Dimitrijevic, Milan ^d   Saltuari, Leopold ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Institute for Rehabilitation and Research   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Dept of Neurologic Rehabilitation ^*  (Belgium)

Author keywords

Baclofen; Brain injury; Cerebral palsy; Drug therapy; Intrathecal infusion; Stroke

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; DANTROLENE; DIAZEPAM;

ARTICLE; BRAIN INJURY; CEREBRAL PALSY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DECUBITUS; HUMAN; INTRATHECAL DRUG ADMINISTRATION; JOINT CONTRACTURE; MAINTENANCE THERAPY; ORAL DRUG ADMINISTRATION; ORTHOPEDIC SURGERY; PATIENT CARE; PATIENT EDUCATION; PATIENT SATISFACTION; PATIENT SELECTION; PERIOPERATIVE PERIOD; PHYSIOTHERAPY; QUALITY OF LIFE; RHIZOTOMY; SCREENING TEST; SELF CARE; SPASTICITY; SPEECH; TREATMENT OUTCOME;

EID: 0033001637     PISSN: 10947159     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1403.1999.00120.x     Document Type: Article

References (42)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds Spasticity: Disordered Motor Control. Chicago: Year Book Medical Publishers; 1980; 485-494.
2. Coffey JR, Cahill D, Steers W et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78: 226-232.
3. Meythaler JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg 1997;87:415-419.
4. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265: 1418-1422.
5. Albright AL, Barry MJ, Painter MJ, Shultz B. Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J Neurosurg 1998;88:73-76.
6. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996;11:77-83.
7. Dabney KW, Lipton GE, Miller F. Cerebral palsy. Curr Opin Pediatr 1997;9:81-88.
8. Gerszten PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg 1998; 88:1009-1013.
9. Becker R, Alberti O, Bauer BL. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 1997;244: 160-166.
10. Albright AL. Intrathecal baclofen therapy for severe spasticity. Exceptional Parent Nov. 1996.
11. Yarkony GM, Sahgal V.. Contractures. A major complication of craniocerebral trauma. Clin Orthop 1987;219:93-96.
12. Joint Section on Neurotrauma and Critical Care and the American Association of Neurological Surgeons and the Brain Trauma Foundation. Guidelines for the management of severe head injury. Washington, DC. Brain Injury Association; 1995.
13. Young RR, Delwaide PJ. Drug therapy: spasticity (first of two parts). N Engl J Med 1981;304:28-33.
14. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981;304:96-99.
15. Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil 1996;77:461-466.
16. Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrell K. Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. J Neurosurg 1997;87:409-414.
17. Rawlins P. Intrathecal baclofen for spasticity of cerebral palsy: project coordination and nursing care. J Neurosci Nurs 1995;27:157-163.
18. Lagueny A, Burbaud P. Botulism toxin: mechanism of action, clinical indication, and results of treatment [in French]. Neurophysiol Clin 1996;26:216-226.
19. Gooch JL, Sandel TV. Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil 1996;77:508-511.
20. Sanchez-Carpintero R, Narbona J. Botulinum toxin in spastic infantile cerebral palsy: results in 27 cases during one year [in Spanish]. Rev Neurol 1997;25:531-535.
21. Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology 1996;47:939-944.
22. Glenn MB. Nerve blocks. In: Glenn MB, Whyte J, eds The Practical Management of Spasticity in Children and Adults. Philadelphia: Lea & Febiger; 1990: ch 11.
23. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985;17:107-116.
24. Knutsson E, Lindblom U, Mrtensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974;23:473-484.
25. Van Hemert JCJ. A double-blind comparison of baclofen and placebo in patients with spasticity of cerebral origin. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Chicago:Yearbook Medical; 1980:41-49.
26. Rice GP. Pharmacotherapy of spasticity: some theoretical and practical considerations. Can J Neurol Sci 1987;14 (Suppl.):510-512.
27. Penn RD, Savoy SM, Corcos D et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320:1517-1521.
28. Muller H, Zierski J, Dralle D, Krauss D, Mutschler E. Pharmacokinetics of intrathecal baclofen. In: Muller H, Zierski J, Penn RD, eds Local-Spinal Therapy of Spasticity. Berlin:Springer;1988:223-226.
29. Penn RD. Intrathecal baclofen for severe spasticity. Ann NY Acad Sci 1988;531:157-166.
30. Albright AL, Barren WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2475-2477.
31. Dralle D, Muller H, Zierski J, Klug N. Intrathecal baclofen for spasticity. Lancet 1985;2:1003.
32. Zierski J, Muller L, Dralle D, Wurdinger T. Implanted pump systems for treatment of spasticity. Acta Neurochir 1988;43 (Suppl):94-99.
33. Ivanhoe C. Intrathecal baclofen therapy for brain injury and stroke. Presented at the 4th International Congress of the Neuromodulation Society; September 17 1998; Lucerne, Switzerland.
34. Albright AL. Intrathecal baclofen in cerebral palsy movement disorders. J Child Neurol 1996;11 (Suppl. 1): S29-S35.
35. Data on file. Medtronic, Inc., 1999. Available at www.medtronic.com
36. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992; 77:236-240.
37. Nuttin B. Intrathecal baclofen therapy for cerebral palsy. Presented at the 4th International Congress of the Neuromodulation Society; September 17 1998; Lucerne, Switzerland.
38. Saltuari L, Kronenberg M, Marosi MJ et al. Long-term intrathecal baclofen treatment in supraspinal spasticity. Acta Neurol (Napoli) 1992;14:195-207.
39. Muller H. Treatment of severe spasticity: Results of a multicenter trial conducted in Germany involving the intrathecal infusion of baclofen by an implantable drug delivery system. Dev Med Child Neurol 1992;3: 739-745.
40. Middel R, Kuipers-Upmeijer H, Bouma J et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997;63:204-209.
41. Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987; 66:181-185.
42. Penn RD, York MM, Paice JA. Catheter systems for intrathecal drug delivery. J Neurosurg 1995;83:215-217.